Gene

MET

MET proto-oncogene, receptor tyrosine kinase

Explore in graph →CI-GENE-00012412HGNC:7029 ENSG00000105976 NCBI 4233 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (140)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 51–100 of 140 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MET D1010Y1
Crizotinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID4778 In a lung adenocarcinoma patient harboring a MET D1010Y mutation, a partial response to crizotinib monotherapy was reported. The patient was treated with crizotinib for 7 months; treatment was ongoing…

Cohorts

Alteration frequency by cohort (132)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved132 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm

Literature

Linked publications (30)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 30 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
· N Engl J Med · 2020 · PMID 32877583 · validated civic_curation pubmed
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
· Lancet Oncol · 2017 · PMID 28958504 · validated civic_curation pubmed
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
· Cell · 2015 · PMID 26359985 · validated civic_curation pubmed
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
· J Clin Oncol · 2013 · PMID 23213094 · validated

MET D1228N1
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID1652 Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation. PMID 27343442 · Heist et al., 2016 · Open in CIViC	civic

MET D1228N1

Crizotinib

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Resistance

accepted

EID1652

Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation.

PMID 27343442 · Heist et al., 2016 · Open in CIViC

MET D1228V2
Cabozantinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	4	accepted	EID1864 Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savoli… (full text at CIViC) PMID 27694386 · Bahcall et al., 2016 · Open in CIViC	civic
Savolitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	4	accepted	EID1865 Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savoli… (full text at CIViC) PMID 27694386 · Bahcall et al., 2016 · Open in CIViC	civic

MET Exon 14 Skipping Mutation42
(prognostic)	Lung Adenosquamous CarcinomaALIAS	Prognostic	C	Supports Poor Outcome	2	submitted	EID11411 A 33-year old male patient (non-smoker) was diagnosed with Stage IVB adenosquamous lung carcinoma. Various treatment strategies were tried but all had progressive disease quickly after treatment. Next… (full text at CIViC) PMID 33854337 · Jiao et al., 2021 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID12840 Human embryonic kidney 293T cells were used in far-Western analysis experiments, which showed that Y1003 binds directly to the c-Cbl TKB domain in MET. When Y1003 was replaced with a non-phosphorylata… (full text at CIViC) PMID 15123609 · Peschard et al., 2004 · Open in CIViC	civic
Cabozantinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID11400 A 77-year-old Caucasian woman (previous smoker) was diagnosed with stage IV adenocarcinoma with pleural disease. Initial genetic testing showed wild-type EGFR and ALK. She received six cycles of carbo… (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC	civic
Capmatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID8847 In a phase 2 trial, a total of 364 patients with non-small cell lung cancer and MET alterations were assigned to cohorts based on prior treatment and type of MET alteration. A total of 97 patients, fr… (full text at CIViC) PMID 32877583 · Wolf et al., 2020 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID1186 A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib. MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+. PMID 25971938 · Frampton et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	submitted	EID7795 An 82 year old with metastatic NSCLC had disease recurrence 39 months after complete surgical resection. Genomic profiling of the primary resection harbored a MET variant c.3028G>C, as well as a frame… (full text at CIViC) PMID 25971938 · Frampton et al., 2015 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11417 A 65-year old female (non-smoker) presented with right leg pain and edema. Percutaneous needle biopsy was performed on a mass-like lesion that appeared in a chest x-ray and revealed moderately differe… (full text at CIViC) PMID 36072511 · Kim et al., 2022 · Open in CIViC	civic
〃	Malignant Lung Neoplasm	Predictive	C	Supports Adverse Response	3	submitted	EID11459 An 84-year old man (smoker) presented with non-small-cell and small-cell lung cancer harboring MET exon 14 skipping mutations and brain metastases. Patient developed progression after eight months of … (full text at CIViC) PMID 34118303 · Mohan et al., 2022 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Adverse Response	2	submitted	EID11409 A 68-year old male (former smoker: 50 pack-years) was diagnosed with stage IV lung adenocarcinoma with pleural disseminations and positive intra-abdominal lymph node. Analysis of tumor tissue showed a… (full text at CIViC) PMID 33347701 · Kanemura et al., 2021 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID7797 MET exon 14 skipping was modelled in vitro by expressing human MET cDNA with exon 14 deletion in HEK293 cells and mouse MET with homologous exon 15 deletion in NIH3T3 cells. NIH3T3 cells expressing ME… (full text at CIViC) PMID 25971938 · Frampton et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID12866 H596 cells harboring mutant c-MET due to exon 14 deletion were shown to be sensitive to capmatinib (INCB28060) inhibiting phospho-c-MET in in vitro ELISA studies. IC50s were 0.4 nM for H596 cells. Cap… (full text at CIViC) PMID 21918175 · Liu et al., 2011 · Open in CIViC	civic
Carboplatin/Pemetrexed Regimen + PembrolizumabCombination	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11487 An 81-year old man (smoker: 40 cigarettes/day) presented with metastatic lung adenocarcinoma. No genetic variants appeared on first round genetic testing on the Oncomine Dx Target TEst Multi-CDx syste… (full text at CIViC) PMID 37007311 · Nitta et al., 2023 · Open in CIViC	civic
Crizotinib	Malignant Gastric Neoplasm	Predictive	B	Supports Sensitivity Response	4	submitted	EID11377 4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against crizotinib, which showed… (full text at CIViC) PMID 26375439 · Lee et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	submitted	EID11416 780 patients with lung cancer were included in this retrospective study. 16 patients with MET mutations were identified, consisting of 7 with MET exon 14 skipping mutations. Analysis of survival of th… (full text at CIViC) PMID 35679833 · Shalata et al., 2022 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID7640 Patients with non-small cell lung carcinoma harboring MET alterations were treated with crizotinib. MET amplification was defined as more than or equal to 6 copies. The response rate at 2 cycles in pa… (full text at CIViC) PMID 31584608 · Moro-Sibilot et al., 2019 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID11379 4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against crizotinib, which showed… (full text at CIViC) PMID 26375439 · Lee et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	1	accepted	EID7642 Pts with MET exon 14-altered NSCLC were enrolled into an expansion cohort of the phase I PROFILE 1001 study (NCT00585195) and received crizotinib. Responses were assessed. By data-cut off 18 pts with … (full text at CIViC) Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID797 We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping. PMID 25971939 · Paik et al., 2015 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID1185 A single patient with a MET c.3028G>A (splice donor site of exon 14) mutation exhibited clinical sensitivity to the c-Met inhibitor crizotinib. Exon 14 skipping was detected using qRT-PCR. Response to… (full text at CIViC) PMID 26729443 · Awad et al., 2016 · Open in CIViC	civic
〃	Histiocytic And Dendritic Cell CancerUNRESOLVED	Predictive	C	Supports Sensitivity Response	3	accepted	EID7796 An 84 year old never-smoker with an upper chest mass was found to have stage 3 histiocytic sarcoma. Genomic profiling discovered a MET exon 14 variant c.2888-5_2944del62, as well as TP53 p.R175H and Z… (full text at CIViC) PMID 25971938 · Frampton et al., 2015 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11384 A 68-year old woman (former smoker: 24 pack-years) was diagnosed with advanced lung adenocarcinoma. Genomic profiling yielded MET exon 14 skipping mutation (c.e14 1 G>A), PIK3CA mutation (c.1624 G>A),… (full text at CIViC) PMID 26791794 · Jorge et al., 2015 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11395 A 59-year old woman was diagnosed with lung adenocarcinoma after a 15 cm right upper lobe lung mass was found with multiple lymph nodes and pleural nodules. Next-generation sequencing revealed a MET e… (full text at CIViC) PMID 30553716 · Rotow et al., 2019 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11398 A 67-year old Asian woman (non-smoker) was diagnosed with stage IV adenocarcinoma with pleural and rib disease. The patient underwent a lobectomy and then received carboplatin/paclitaxel/bevacizumab. … (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID1651 Case report of a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and major response to crizotinib. PMID 26845194 · Shea et al., 2016 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID7643 In this case Report, a 67-year old female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of c… (full text at CIViC) PMID 26892698 · Mahjoubi et al., 2016 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Resistance	2	submitted	EID11391 A 60-year old woman (non-smoker) was diagnosed with stage IV lung adenocarcinoma after finding a 5.7 x 5.1 cm left pleural-based mass with multiple invasions. The patient was put on carboplatin and pe… (full text at CIViC) PMID 27987579 · Dong et al., 2016 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Does Not Support Sensitivity Response	2	submitted	EID11399 A 77-year-old Caucasian woman (previous smoker) was diagnosed with stage IV adenocarcinoma with pleural disease. She received six cycles of carboplatin/pemetrexed which was followed by pemetrexed main… (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID11401 A 62-year old Asian man (non-smoker) was diagnosed with stage IV adenocarcinoma with pleural metastases. He received pemetrexed, docetaxel, nivolumab, and gemcitabine. Genetic testing revealed MET exo… (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	1	accepted	EID4786 In a never-smoking metastatic lung adenocarcinoma patient harboring a MET splice site mutation (c.2887-18_2887-7del12) treated with crizotinib monotherapy, was associated with a response as evident … (full text at CIViC) PMID 25769807 · Jenkins et al., 2015 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID736 The creation of a cell line model (HEK293) with MET exon 14 deletion (using the CRISPR/Cas9 system) led to enhanced cellular growth and sensitivity to the MET inhibitor crizotinib. MET exon 14 deletio… (full text at CIViC) PMID 26547802 · Togashi et al., 2015 · Open in CIViC	civic
Cabozantinib + CrizotinibSequential	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11410 A 77-year old woman was diagnosed with lung adenocarcinoma harboring a MET exon 14 skipping mutation after PET-CT scans showed a right upper lobe mass, right hilar enlarged lymph nodes, and multiple b… (full text at CIViC) PMID 33530219 · Qin et al., 2021 · Open in CIViC	civic
SAIT301	Malignant Gastric Neoplasm	Predictive	B	Supports Sensitivity Response	3	submitted	EID11378 4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against SAIT301, a monoclonal an… (full text at CIViC) PMID 26375439 · Lee et al., 2015 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID11380 4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against SAIT301, a monoclonal an… (full text at CIViC) PMID 26375439 · Lee et al., 2015 · Open in CIViC	civic
Savolitinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11474 A 49-year old female (non-smoker) presented with a 3.8 x 2.9 cm mass that was diagnosed as Stage IIIA lung adenocarcinoma. Genetic testing revealed a MET exon 14 skipping mutation, to which the patien… (full text at CIViC) PMID 36052259 · Fu et al., 2022 · Open in CIViC	civic
Tepotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	submitted	EID8848 In this open-label phase 2 trial, MET inhibitor tepotinib was administered to patients with non-small cell lung cancer and MET exon 14 skipping mutation found in either liquid and/or tissue biopsy. A … (full text at CIViC) PMID 32469185 · Paik et al., 2020 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	submitted	EID11766 In the VISION phase 2 trial (NCT02864992), 313 patients with advanced, metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations were treated with 500 mg/kg tepotinib daily. In t… (full text at CIViC) PMID 37270698 · Mazieres et al., 2023 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID7272 In a interim analysis of Phase II trial for MET exon 14 skipping NSCLC, 34 patients received MEK selective inhibitor tepotinib. 9/15 (60.0%) evaluable patients had a confirmed PR and 3 (20.0%) had SD.… (full text at CIViC) Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	4	submitted	EID11465 A 56-year old male (smoker: 50 pack-years) was diagnosed with stage IIIA lung adenocarcinoma. Patient underwent four cycles of cisplatin and pemetrexed and maintenance therapy with pemetrexed but was … (full text at CIViC) PMID 33387444 · Tanaka et al., 2021 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	submitted	EID11415 An 84-year old man (smoker: 62-pack-years) was diagnosed with stage IVB non-small-cell lung cancer (NSCLC) and was started on carboplatin and nab-paclitaxel. After the tumor progressed, the patient wa… (full text at CIViC) PMID 35383870 · Tanaka et al., 2022 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11476 A 57-year female (non-smoker) was diagnosed with lung adenocarcinoma via pleural fluid cytology. After multigene testing revealed MET exon 14 skipping mutation, the patient was switched from cisplatin… (full text at CIViC) PMID 36810936 · Ikeo et al., 2023 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID11464 A 75-year old woman presented with lung adenocarcinoma (stage IVA) to which next-generation sequencing revealed METex14del. The patient was put on crizotinib (500 mg/day) and showed partial response f… (full text at CIViC) PMID 33533182 · Takamori et al., 2021 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID11477 A 60-year old male (smoker: 38 pack-years presented with stage IIB lung adenocarcinoma. After receiving an upper lobectomy, the left lobar lymph node was pathologically positive and received cisplati… (full text at CIViC) PMID 37228358 · Onodera et al., 2023 · Open in CIViC	civic

CD274 Overexpression + MET Exon 14 Skipping MutationCD274 MET2
Carboplatin/Pemetrexed Regimen + PembrolizumabCombination	Lung Sarcomatoid Carcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID11457 A 65-year old male (non-smoker) presented with advanced sarcomatoid non-small-cell lung cancer harboring a MET exon 14 skipping mutation with elevated PDL1 levels (tumor proportion score of 80%). Afte… (full text at CIViC) PMID 35871685 · Gonugunta et al., 2022 · Open in CIViC	civic
Nivolumab	Lung Sarcomatoid Carcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11414 A 58-year old male (non-smoker/non-drinker) was diagnosed with metastatic adenocarcinoma with sarcomatoid components. A tissue sample revealed a MET exon 14 skipping mutation and the patient was treat… (full text at CIViC) PMID 35110965 · Gu et al., 2022 · Open in CIViC	civic